On September 18, the U.S. Food and Drug Administration (FDA) approved Opioid Analgesic Risk Evaluation and Mitigation Strategy plan, which for the first time applies to immediate-release opioid analgesics intended for use in an outpatient setting. Read more via Food & Drug Administration.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder